Central Nervous System Non-hodgkin Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2018-07-20
Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial of Yttrium-90 ibritumomab tiuxetan with rituximab for primary CNS non-Hodgkin lymphoma has terminated with results posted.